Research Article

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Abstract

Background: Although numerous studies have established the sensitivity and specificity of Ioflupane I123 Injection (ioflupane (^{123}I), (^{123}I) FP-CIT, DaTscan™, or DaTSCAN™) imaging in patients with movement disorders or dementia, no studies have examined the effects of gender and age on diagnostic performance. **Methods:** We pooled data from four clinical trials in which patients with a movement disorder or dementia and healthy volunteers were administered ioflupane (^{123}I). Panels of 3-5 blinded experts and/or on-site nuclear medicine physicians rated the images as normal or abnormal. Results were compared with expert clinical diagnosis (reference standard) to determine sensitivity and specificity. Subgroup and multiple logistic regression model (MLRM) analyses were performed to evaluate the effect of gender and age (two groups: <65 *vs.* ≥65 yrs and <75 *vs.* ≥75yrs) on sensitivity and specificity.

Results: There were 421 males and 305 females in the intent-to-diagnose population. Sensitivity was higher for males with parkinsonian syndrome (PS) (93.3% *vs.* 87.6%; P=0.0029), whereas specificity was higher for females (96.4% *vs.* 89.5%; P=0.0126). Sensitivity was higher in the younger age groups (<65yrs, 91.0% *vs.* ≥65 yrs, 86.8%; P=0.0240 and <75yrs, 90.7% *vs.* ≥75yrs, 78.4%, P <0.0001). Specificity was higher in subjects <65 yrs (94.0% *vs.* 89.7% for ≥65yrs, P=0.0384). Analysis using the 75yrs cutoff showed no differences. When MLRM was used, all covariates (disease state, age, gender, reader type, and follow-up duration) were significant predictors of the model effect on sensitivity. For specificity, only disease state and reader type were significant predictors.

Conclusions: Sensitivity and specificity of ioflupane (^{123}I) imaging was high in all age and gender subgroups, though statistically significant differences were observed with a slightly reduced, though still diagnostically useful, sensitivity above 75yrs. This reduced sensitivity may be due to increased frequency of mixed pathologies in older people, which makes the clinical diagnosis (reference standard) less optimal. In PS, sensitivity was higher in males, whereas specificity was higher in females. MLRM analysis demonstrated that all tested covariates (including gender and age) were significant predictors for sensitivity, but not for specificity.

Keywords: Diagnostic accuracy; Sensitivity; Specificity; SPECT, Ioflupane I123 Injection; Ioflupane (^{123}I); (^{123}I)FP-CIT; DaTscan™; DaTSCAN™; Gender; Age; Parkinsonian syndrome; Dementia; Lewy bodies

Volume 1 Issue 2 - 2014

Donald G Grosset,[1,2] John T O'Brien,[3] Wolfgang H Oertel,[4] Ian G McKeith,[5] Zuzana Walker,[6] Klaus Tatsch,[7] Eduardo Tolosa,[8] Paul F Sherwin,[9] Igor D Grachev[10]

[1]Institute of Neurological Sciences, Southern General Hospital, Scotland
[2]Department of Neuroscience, University of Glasgow, Scotland
[3]Department of Psychiatry, University of Cambridge School of Clinical Medicine, UK
[4]Department of Neurology, Philipps-University of Marburg, Germany
[5]Department of Old Age Psychiatry, Newcastle University, UK
[6]Mental Health Sciences Unit, University College London, UK
[7]Department of Nuclear Medicine, Municipal Hospital Karlsruhe, Germany
[8]Department of Neurology Service, University of Barcelona, Spain
[9]Clinical Development, Life Sciences, GE Healthcare, USA
[10]Medical Affairs, Life Sciences, GE Healthcare, USA
[§]These authors contributed equally to this work

Correspondence: Donald G Grosset, Institute of Neurological Sciences, Southern General Hospital and Department of Neurology, University of Glasgow, Glasgow Scotland, G51 4TF, UK, Tel: +44-141-201-2486, Fax+44-141-447-0618, Email donaldgrosset@gmail.com

Igor D Grachev, Medical Affairs, GE Healthcare- Life Sciences, 101 Carnegie Center, Princeton, New Jersey 08540, USA, Email grachevi@hotmail.com

Abbreviations: AD, alzheimer's disease; BIE, blinded image evaluation; CI, confidence interval; DaT, dopamine transporter; DLB, dementia with lewy bodies; ET, essential tremor; FN, false negative; FP, false positive; ITD, intent to diagnose; MSA, multiple system atrophy; NPA, negative percent agreement; PD, parkinson's disease; PP, per protocol; PPA, positive percent agreement; PS, parkinsonian syndrome; PSP, progressive supranuclear palsy; SDD, striatal dopaminergic deficit; SDDD, striatal dopaminergic deficit disorder; SPECT, single-photon emission computed tomography; TN, true negative; TP, true positive; VaD, vascular dementia; yrs, years

Introduction

The use of radiopharmaceuticals to augment clinical diagnosis of neurological diseases has facilitated greater accuracy and confidence in medical decision-making. Improved accuracy, particularly in the early stages of disease, allows for more suitable treatment selection and avoids unnecessary and potentially harmful exposure to inappropriate medications. Interpretation of the images requires expert understanding and ability to discriminate normal images from abnormal images. This expertise further relies upon the ability to understand and recognize the differences that exist and changes that occur based on gender and the normal aging process, respectively. Early studies established that changes occur normally in the brain with aging 1,2. Dopamine transporter (DaT) imaging studies performed in healthy volunteers have shown that DaT uptake decreases with age in a linear manner, declining 4.1-7.5% per decade, depending upon the region of the brain examined 3-6. Likewise, specific-to-non-specific DaT binding ratios appear to be higher in healthy females than males 4-6 and this difference is not age-related 5. In the PRamipexole On Underlying Disease (PROUD) study, a decline of 14.2%-15.5% was seen in early Parkinson's disease over 15 months, but effects of age and gender were not analyzed 7,8.

While some knowledge exists addressing the effects of gender and age on DaT uptake in healthy volunteers, no analyses have

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al.

43

been performed to show the effects of gender and age on diagnostic performance in patients with movement disorders or dementia. Several clinical trials have evaluated the sensitivity (equivalent to positive percent agreement (PPA)) and specificity (equivalent to negative percent agreement (NPA)) of using Ioflupane I123 Injection (ioflupane (^{123}I) or (^{123}I) FP-CIT or DaTSCAN™ or DaTscan™) and single-photon emission computed tomography (SPECT) imaging to detect the presence or absence of a striatal dopaminergic deficit (SDD) in subjects with parkinsonian syndrome (PS) and dementia with Lewy bodies (DLB) 9-15. PS and DLB may have interrelated symptoms; cognitive impairment may be present in PS and motor symptoms may manifest in subjects with DLB. Hence, evaluating the disease states individually, as well as combined, may be informative. To perform such analyses, large datasets are needed. We pooled four clinical trials presented for the US new drug application of ioflupane (^{123}I) to examine the effects of gender and age on the diagnostic performance of ioflupane (^{123}I) imaging.

Materials and methods

Four clinical trials 9-12,14,15 were used for this subgroup analysis.

These clinical trials had been used to support the ioflupane (^{123}I) US new drug application. Each study had evaluated the sensitivity (PPA) and specificity (NPA) of ioflupane (^{123}I) (Ioflupane I123 Injection or DaTscan™ or DaTSCAN™, GE Healthcare, Amersham, UK) imaging to detect the loss of dopaminergic nigrostriatal neurons in subjects thought to have a suspected movement disorder and/or dementia. The reference standard used in each of these trials was expert clinical diagnosis at baseline and 1-3 years post-scan. Table 1 summarizes the key characteristics of the four clinical trials (studies). All studies complied with the current revision of the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice Consolidated Guideline and applicable national and local laws. Ethics Committees or Institutional Review Boards approved the study protocols and amendments (Table 2). Written informed consent was given by all subjects or their guardians after the study aims, methods, anticipated benefits, and potential hazards were explained to them and prior to initiating any study procedures or assessments. The studies' informed consents did not provide for publication of patient data; however, they included provisions for subsequent analyses, such as this subgroup analysis.

Table 1 Key characteristics of four clinical studies included in age and gender reported analysis

Study	Study A[10]	Study B[9,11]	Study C[12]	Study D[14,15]
Key Characteristics (Phase, Design)	• Phase 3 • Multicenter, open-label, non-randomized • Single-dose • No control used	• Phase 3 • Multicenter, open-label, non-randomized • Single-dose • No control used	• Phase 3 • Multicenter, open-label, non-randomized • Repeat-dose (max. of 3) • No control used	• Phase 4 • Multicenter, open-label, non-randomized • Single-dose • No control used
Reference Standard	• Expert clinical diagnosis at baseline according to published consensus criteria as the RCD • No clinical panel used	• Expert clinical diagnosis at 12 months as the RCD • Clinical panel of 3 dementia experts	• Expert clinical diagnosis at 36 months as the RCD • Review of videotapes by 2 independent movement disorder experts	• Expert clinical diagnosis at 24 months as the RCD • No clinical panel used
Subjects	• Healthy volunteers • Subjects with Parkinson's disease, Multiple system atrophy, Progressive supranuclear palsy, or Essential tremor	• Subjects with dementia (possible DLB or other dementia types AD, VaD)	• Healthy volunteers • Subjects with Early Parkinson's disease, or Tremor (mainly essential tremor)	• Subjects with movement disorders (an uncertain clinical diagnosis of PS)
Objectives	• Primary Sensitivity and specificity for detecting or excluding an SDD • Secondary Inter-reader agreement	• Primary Sensitivity and specificity for detecting or excluding an SDD • Secondary Inter-reader agreement	• Primary Sensitivity and specificity for detecting or excluding an SDD • Secondary Inter-reader agreement	• Primary [a] Impact of ioflupane (^{123}I) image assessments on patient diagnoses, confidence of diagnosis, and clinical management • Secondary Sensitivity and specificity for detecting or excluding an SDD

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al. 44

Table Continued....

Study				
	Study A[10]	**Study B[9,11]**	**Study C[12]**	**Study D[14,15]**
Investigational product dose information	Ioflupane (^{123}I) 111-185 MBq (3 to 5 mCi) iv, 1 dose	Ioflupane (^{123}I) 111-185 MBq (3 to 5 mCi) iv, 1 dose	Ioflupane (^{123}I) 111-185 MBq (3 to 5 mCi) iv, 3 doses 18 months apart	Ioflupane (^{123}I) 111-185 MBq (3 to 5 mCi) iv, 1 dose (73 subjects) or 2 doses 24months apart (14 subjects)
No. of study sites	6	40	10	15
No. of subjects entered in the study/ completed efficacy evaluations	250/220	351/288	202/102	125/118
Age of ITD population, range (mean)	40, 80 (62.7)	54, 90 (73.9)	33, 79 (60.4)	25, 84 (64.2)
Gender	62% male, 38% female	57% male, 43% female	56% male, 44% female	53% male, 47% female
Blinded image evaluations performed	Yes (5 central readers)	Yes (3 central readers)	Yes (3 central readers)	No (on-site readers only)

[a]Primary objective was to assess clinical utility of ioflupane (^{123}I) images, however, images were used for age and gender subgroup analysis. AD, alzheimer's disease; DLB, dementia with lewy bodies; ITD, intent to diagnose; MBq, megabecquerel; PS, parkinsonian syndrome; RCD, reference clinical diagnosis; SDD, striatal dominergic deficit; VaD, vascular dementia.

Table 2 Ethics committees for the four studies in the sub group analysis.

Study A			
Committee Name	**City**	**Country**	**Chairman**
Medical Research Ethics Committee, The Phillips University Clinic	Marburg	Germany	Dr. P Heubel
The Faculty of Medicine Ethics Committee, Ludwig Maximilian University of Munich	Munich	Germany	Prof. Dr. med. Dent. W Gernet
Southern General Hospital Medical Ethics Committee	Glasgow	UK	Rev. D Keddie
Medical Ethics Committee, Academic Medical Center, Amsterdam University	Amsterdam	The Netherlands	Prof. L Arisz
Joint UCL/UCLH Committees on the Ethics of Human Research	London	UK	Prof. A McLean
Ethics Review Committee, University Hospital	Ghent	Belgium	Prof. Dr. M Bogaert
Ethikkommission des Landes Oberösterreich	Linz	Austria	Univ. Prof. Prim Dr. Fisher
Ethik-Kommission der Medizinischen Fakultät der Universität Wien und des Allgemeinen Krnkenhauses der Stadt Wien AKH	Wien	Austria	Univ. Prof. Dr. E Singer
Comité consultative pour la protection des personnes dans la recherché biomédicale Bordeaux B	Bordeaux	France	Prof. MC Saux
Ethik-Kommission an der Medizinischen Fakultät der Universität Leipzig	Leipzig	Germany	Prof. Dr. med. R Preiß
Ethikkommission, Campus Charité Mitte	Berlin	Germany	Prof. Dr. med. R Uebelhack
Ethik-Kommission der Ruhr- Universität Bochum, Medizinischen Fakultät	Bochum	Germany	Prof. Dr. Zenz
Ethik-Kommission der Georg-August-Ruhr-Universität Göttingen	Göttingen	Germany	Prof. Dr. med. E Rüther
Ethik-Kommission der Ärztekammer Hamburg	Hamburg	Germany	Prof. Dr. med. Th. Weber
Medizinischen Hochschule Hannover, Ethikkommission	Hannover	Germany	Prof. Dr. HD Tröger
Landesärztekammer Rheinland-Pfalz, Ethikkommission	Mainz	Germany	Prof. Dr. Rittner
Kommission für Ethik in der ärztlichen Forschung. Bereich Humanmedizin, Klinikum der Philipps- Universität Marburg	Marburg	Germany	Prof. Dr. Med. G Richter

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al. **45**

Table Continued....

Study A

Committee Name	City	Country	Chairman
Regione Veneto, Aziendo Ospedaliera di Padova, Comitato Etico per la Sperimentazione	Padova	Italy	Dr. R Pegoraro
Azienda Ospedaliera Pisana, Comitato etico per la studio del farmaco sull' uomo	Pisa	Italy	Prof. R Barsotti
Regional komité for medisinsk forskninsetikk, Vest-Norge (REK Vest), Universitetet i Bergen, det medisinske fakultet	Bergen	Norway	A Berstad
Comité Ético de Investigação Clinica	Porto	Portugal	
Karolinska Institutet, Forskningsettikkommitté Syd	Stockholm	Sweden	Prof. H Glaumann
Regionala etikprövningsnämnden i Stockholm	Stockholm	Sweden	Prof. LE Rutquist
Clinic Barcelona, Hospital Universitari, Comitè ètic investigaciò clinica	Barcelona	Spain	
Comité Etico de Investigación Clinica, Hospital Universitario de Getafe	Madrid	Spain	
Comité etico de investigación clinica Hospital "La Fe" Valencia	Valencia	Spain	
Northern and Yorkshire Multi-Centre Ethics Committee, Durham University	Durham	UK	J Kelly/S Brunton-Shiels
Gateshead Local research Ethics Committee	Sunderland	UK	Dr. DG Raw
Northumberland, Tyne and Wear NHS Strategic Health Authority Local Research Ethics Committees, Newcastle General Hospital	Newcastle upon Tyne	UK	Dr. J Lothian, PD Carr
Southampton & South West Hampshire Local Research Ethics Committee	Southampton	UK	C Wright
Ethikkommission der Medizinischen Fakultät der Ludwig-Maximilans-Universität, LMU, Klinikum Großhadern	München	Germany	Prof. Dr. G Paumgartner
Ethikkommission der Fakultät für Medizin der Technischen Universität München	München	Germany	Prof. Dr. A Schömig
Aligemeines öffentliches Krankenhaus der Stadt Linz, Kommission zur Beurteilung klinischer Prüfungen von Arzneimitteln, Ethikkommission	Linz	Austria	Primar Dr. H Stekel
Ospedali Civili Brescia, Aziendo Ospedaliera, Comitato Etico	Brescia	Italy	Prof. F De Ferrari
Fakultní nemocnice v Motole, Etickákomise	Prague	Czech Republic	MUDr. V Šmelhaus
Brighton and Sussex Local Research Ethics Committee	Brighton	UK	Dr. P Seddon
East Sussex Local Research Ethics Committee	Brighton	UK	Dr. J Rademaker
South Manchester Local Research Ethics Committee	Manchester	UK	Dr. W Pettit
Central Manchester Research Ethics Committee	Manchester	UK	Dr. D Mandal
NHS Tayside Board, Tayside Committee on Medical Research Ethics, Ninewells Hospital & Medical School	Dundee	UK	NF Brown
Fazio-Fondazione San Raffaele Del Monte Tabor Milano, Comitato Etico Dell'istituto Nazionale Neurologico Besta di Milano	Milano	Italy	Prof. E Müller
IRCCS – Fondazione San Raffaele Del Monte Tabor di Milano	Milano	Italy	Prof. G Zoppei
Comité ético de investigación clínica, Servicio Andaluz de Salud, Consejería de Salud, Hospitales Universitarios Virgen de Rocío de Sevilla	Sevilla	Spain	
Ethikkommission der stadt Wien	Wien	Austria	Dr. H Serban
North Sheffield Local Research Ethics Committee, Northern General Hospital	Sheffield	UK	Dr. GPM Clark
Glasgow West Local Research Ethics Committee	Glasgow	UK	Dr. J Hunter
NHS Greater Glasgow Primary Care Division Local Research Ethics Committee, Gartnavel Royal Hospital	Glasgow	UK	Dr. P Fleming
Frenchay Research Ethics Committee, North Bristol NHS Trust Headquarters	Bristol	UK	Drs. J Kendall and M Shere
Ärztekammer Berlin, Ethik-Kommission	Berlin	Germany	C Biondo

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al. **46**

Table Continued....

Study A

Committee Name	City	Country	Chairman
Ethikkommission des Landes Bremen, Institut für Klinische Pharmaakologie, Klinikum Bremen-Mitte	Bremen	Germany	Dr. K Boomgaarden-Brandes
Ethikkommission der Fakultät für Medizin der Technischen Universität München	München	Germany	Prof. Dr. A Schömig
Ethics Committee of the Southern General Hospital NHS Trust, Glasgow	Glasgow	UK	Rev. D Keddie
Kommission für Ethik in der Ärztlichen Forschung, Klinikum der Philipps-Universität Marburg	Marburg	Germany	Prof. Dr. med. G Richter
New Cross Hospital Local Research Ethics Committee	Wolverhampton	UK	DJ Little
Southampton and South West Hampshire Joint Local	Southampton	UK	Dr. A Kermode
Joint Ethics Committee Newcastle and North Tyneside Health Authority	Newcastle	UK	Prof. PA Heasman
Comite Etico de Investigacion Clinica Hospital Clinic I Provincial	Barcelona	Spain	Prof. J Rodes
Comite Etico de Investigacion Clinica del Hospital de la Santa Creu I Sant Pau	Barcelona	Spain	FJ Carrenca
Comité d' éthique hospitalier, Cliniques Universitaires de Mont-Godinne	Yvoir	Belgium	Dr. P Evrard
Hospitais da Universidade de Coimbra	Coimbra	Portugal	Dr. JA Branquinho de Carvalho
Ethikkommission der Medizinischen Faultät der Universität Innsbruck	Innsbruck	Austria	Univ. Prof. Dr. P Lukas
Hospital Ethical Committee, University Hospital UCL Mont-Godinne	Yvoir	Belgium	Dr. P Evrard
Commission for Ethics, AZ St.-Jan AV	Brugge	Belgium	Dr. J Van Droogenbroeck
Comite Consultatif de Protection des Personnes Dans La Recherche Biomedicale de Lille, Hôpital Huriez	Lille	France	Prof. PY Hatron
Ethik-Kommission der Ärztekammer Hamburg Körperschaft des öffentlichen Rechts	Hamburg	Germany	Prof. Dr. Med. K Held
Ethikkommission des Klinikums der Universität Regensberg	Regensberg	Germany	Prof. Dr. R Andreesen
Vorsitzenden der Ethikkommission Bei der Ärztekammer des Saarlandes	Saarbrücken	Germany	Dr. S Ertz
Spett. Le Comitato Etico	Milano	Italy	Prof. A Randazzo
Comitato Etico Per La Sperimentazione Clinica Del Farmaci	Firenze	Italy	Prof. L Zilletti
Ministério Da Saúde Hospitais Da Universidade De Coimbra	Coimbra	Portugal	Prof. Dr. JM Pedroso Lima
Comité Ético De Investigación Clínica Hospital Clínic I Provincial	Barcelona	Spain	Prof. MA Asenjo Sebastián
Comité Ético De Investigación Clínica Del Hospital De La Santa Creu I Sant Pau	Barcelona	Spain	FJ Carrencá
King's College Hospital	London	UK	Prof. ER Howard
Southampton and South West Hampshire Local Research Ethics Committees	Southampton	UK	Dr. A Kermode
Etik-Kommission Der Medizinischen Faultät der Universität Wien	Wien	Austria	Univ. Prof. Dr. E Singer

Procedures

Each of the four studies key results have been published 9-12,14,15, but not age and gender effects. Briefly, they were open-label, non-randomized, Phase 3 or 4 clinical trials to determine the sensitivity and specificity of ioflupane (^{123}I) imaging to detect or exclude an SDD in subjects with a movement disorder (PS, including Parkinson's Disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP); or essential tremor (ET) and/or dementia (DLB, Alzheimer's disease (AD) or vascular dementia (VaD); and healthy volunteers. Subjects received either one (Studies A and B) or up to 3 (Study C and D [no more than 2]) doses of 111-185 MBq of ioflupane (^{123}I). SPECT imaging was performed 3-6 hours after injection. Ioflupane (^{123}I) images were read on-site (institutional reads) in all 4 studies. In 3 of the studies, images were also read by 3 or 5 independent blinded readers (blinded image evaluation, BIE). Images were classified as normal (SDD absent) or abnormal (SDD present). Expert clinical diagnosis made by neurologists or dementia specialists blinded to imaging results established whether the subject

Age, gender, and diagnostic performance of ioflupane 1123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al.   47

had an SDDD (PD, PS, PSP, MSA, or DLB) or did not have an SDDD (ET, AD or VaD and healthy volunteers). Ioflupane (^{123}I) image results were compared with the corresponding subject's reference clinical diagnosis, made at baseline and 1-3 years post-scan, and classified as True Positive (TP), True Negative (TN), False Positive (FP) or False Negative (FN).

Statistical analysis

All statistical analyses were performed using Statistical Analysis Software (SAS Institute Inc., Cary, NC, USA). Demographic data are presented using descriptive statistics. Populations evaluated in this subgroup analysis were the Intent to diagnose (ITD; all dosed subjects who underwent SPECT imaging and underwent the reference clinical diagnosis assessment for the relevant analysis) and Per protocol (PP; all subjects in the ITD population with no major protocol violations). Sensitivity was calculated as nTP / (nTP+nFN), (n = number of

subjects). Specificity was calculated as nTN / (nTN+nFP). Sensitivity (PPA) and specificity (NPA) were calculated for the ITD and PP populations, and are reported with 95% confidence intervals (CI). Subgroup analyses were performed based on gender (male/female) and age, using 2 arbitrarily set thresholds,

Results

Study participants

The ITD population comprised 726 subjects and the PP population, 622. Subject baseline demographic characteristics and reference clinical diagnosis are shown by study and for the total ITD population in Table 3 and PP population in Table 4. There were no meaningful differences in baseline characteristics between the ITD and PP populations.

Table 3 Subject baseline demographics and clinical diagnosis (Reference Clinical Diagnosis) by study – ITD population

Study		Study A (N = 220)	Study B (N = 326)	Study C (N = 102)	Study D (N=78)	Total (N = 726)
Age (yr)	Mean (SD)	62.7 (8.87)	73.9 (7.17)	60.4 (10.91)	64.2 (11.99)	67.6 (10.60)
	Min, Max	40, 80	54, 90	33, 79	25, 84	25, 90
	Median	63.5	75.0	61.0	67.0	69.0
Gender	Male	136 (62%)	187 (57%)	57 (56%)	41 (53%)	421 (58%)
	Female	84 (38%)	139 (43%)	45 (44%)	37 (47%)	305 (42%)
Race	Caucasian	216 (98%)	326 (100%)	102 (100%)	77 (99%)	721 (99%)
	Black	3 (1%)	0 (0%)	0 (0%)	0 (0%)	3 (<1%)
	Asian	1 (<1%)	0 (0%)	0 (0%)	1 (1%)	2 (<1%)
	Other	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PS (SDDD)		158 (72%)	0 (0%)	71 (70%)	48 (62%)	277 (38%)
Possible PS		158 (72%)	0 (0%)	5 (5%)	48 (62%)	211 (29%)
Probable PS		0 (0%)	0 (0%)	66 (65%)	0 (0%)	66 (9%)
DLB (SDDD)		0 (0%)	116 (36%)	0 (0%)	0 (0%)	116 (16%)
Possible DLB		0 (0%)	27 (8%)	0 (0%)	0 (0%)	27 (4%)
Probable DLB		0 (0%)	89 (27%)	0 (0%)	0 (0%)	89 (12%)
Non-PS/Non-DLB (no SDD)		62 (28%)	126 (39%)	31 (30%)	30 (38%)	249 (34%)
ET		27 (12%)	0 (0%)	14 (14%)	23 (29%)	64 (9%)
AD		0 (0%)	125 (38%)	0 (0%)	0 (0%)	125 (17%)
Other		35 (16%)	1 (<1%)	17 (17%)	7 (9%)	60 (8%)
SDD Present[a]		158 (72%)	116 (36%)[b]	71 (70%)	48 (62%)	393 (54%)
SDD Absent		62 (28%)	126 (39%)[b]	31 (30%)	30 (38%)	249 (34%)

[a]Includes Possible and Probable PS and Possible and Probable DLB diagnoses.

[b]22 subjects had no diagnosis, and 62 subjects were not assessed at 12-month visit.

AD, alzheimer's disease; DLB, dementia with Lewy bodies; ET, essential tremor; ITD, intent to diagnose; N, number of subjects in the study; PS, parkinsonian syndrome; SD, standard deviation; SDD, striatal dopaminergic deficit; SDDD, striatal dopaminergic deficit disorder; yr, year.

Table 4 Demographic characteristics and clinical diagnosis (per Reference Clinical Diagnosis) by study – PP population

Study		Study A (N = 157)	Study B (N = 288)	Study C (N = 100)	Study D (N=77)	Total (N = 622)
Age (yr)	Mean (SD)	63.1 (8.51)	74.2 (7.02)	60.5 (10.97)	64.1 (12.05)	67.9 (10.61)
	Min, Max	40, 80	54, 90	33, 79	25, 84	25, 90
	Median	64.0	75.0	61.5	67.0	69.0
Gender	Male	99 (63%)	160 (56%)	57 (57%)	40 (52%)	356 (57%)
	Female	58 (37%)	128 (44%)	43 (43%)	37 (48%)	266 (43%)

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al.   48

Table Continued....

| Study		Study A (N = 157)	Study B (N = 288)	Study C (N = 100)	Study D (N=77)	Total (N = 622)
Race	Caucasian	153 (97%)	288 (100%)	100 (100%)	76 (99%)	617 (99%)
	Black	3 (2%)	0 (0%)	0 (0%)	0 (0%)	3 (<1%)
	Asian	1 (1%)	0 (0%)	0 (0%)	1 (1%)	2 (<1%)
	Other	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PS (SDDD)		115 (73%)	0 (0%)	69 (69%)	47 (61%)	231 (37%)
Possible PS		115 (73%)	0 (0%)	5 (5%)	47 (61%)	167 (27%)
Probable PS		0 (0%)	0 (0%)	64 (64%)	0 (0%)	64 (10%)
DLB (SDDD)		0 (0%)	110 (38%)	0 (0%)	0 (0%)	110 (18%)
Possible DLB		0 (0%)	25 (9%)	0 (0%)	0 (0%)	25 (4%)
Probable DLB		0 (0%)	85 (30%)	0 (0%)	0 (0%)	85 (14%)
Non-PS/Non-DLB (no SDDD)		42 (27%)	123 (43%)	31 (31%)	30 (39%)	226 (36%)
ET		16 (10%)	0 (0%)	14 (14%)	23 (30%)	53 (9%)
AD		0 (0%)	122 (42%)	0 (0%)	0 (0%)	122 (20%)
Other		26 (17%)	1 (<1%)	17 (17%)	7 (9%)	51 (8%)
SDDD Present[a]		115 (73%)	110 (38%)	69 (69%)	47 (61%)	341 (55%)
SDDD Absent		42 (27%)	123 (43%)	31 (31%)	30 (39%)	226 (36%)

[a]Includes Possible and Probable PS and Possible and Probable DLB diagnoses.

AD, alzheimer's disease; DLB, dementia with lewy bodies; ET, essential tremor; n = number of subjects in the study; PP, per protocol; PS, parkinsonian syndrome; SD, standard deviation; SDDD, striatal dopaminergic deficit disorder.

Effect of gender on diagnostic performance

Figure 1 displays sensitivity (PPA) and specificity (NPA) in males *vs.* females in subjects with PS and DLB (ITD population), measured at baseline and upon follow-up, using BIE results. There were statistically significant differences at baseline in subjects with PS, with sensitivity being lower and specificity higher in females compared with males. This was also true for the whole population (Table 5). At month 18 and month 36, statistically significant differences were not observed. There were no differences between males and females observed in subjects with DLB at any time points. When on-site image reads were used (Table 6), no statistically significant differences were observed between males and females.

Figure 1 Sensitivity (PPA) and specificity (NPA) in males *vs.* females with PS and DLB.

Sensitivity (PPA) and specificity (NPA), read at baseline (BL), and at month 18 (M18) and month 36 (M36) in subjects with PS (parkinsonian syndrome) and at month 12 (M12) in subjects with DLB (dementia with Lewy bodies). *P <0.05; **P <0.01.

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al.   49

Table 5 Sensitivity (PPA) and specificity (NPA) from blinded image evaluation between male and female subjects. Values are mean results across all readers. Intent to diagnose population

Reference Clinical Diagnosis						
	Parkinsonian Syndrome (PS; SDDD)		Dementia with Lewy Bodies (DLB; SDDD)		Whole Population	
	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)
Baseline[a]						
Male (n=318)	93.3 (91.0, 95.1)	89.5 (84.9, 93.1)	81.0 (73.7, 87.0)	87.6 (82.3, 91.8)	90.9% (88.6, 92.8)	88.6 (85.3, 91.4)
Female (n=235)	87.6 (83.9, 90.7)	96.4 (92.3, 98.7)	74.4 (64.2, 83.1)	92.4 (88.0, 95.6)	85.1 (81.6, 88.2)	94.1 (91.3, 96.3)
P value	0.0029	0.0126	0.2568	0.1378	0.0023	0.0062
Month 12[b]						
Male (n=115)			79.7 (72.3, 85.9)	92.7 (87.8, 96.0)		
Female (n=94)			76.4 (66.2, 84.8)	92.9 (88.1, 96.1)		
P value			0.6248	1.0000		
Month 18[c]						
Male (n=57)	78.7 (69.8, 86.0)	93.7 (84.5, 98.2)				
Female (n=45)	79.0 (70.0, 86.4)	100 (88.1, 100)				
P value	1.0000	0.3041				
Month 36[c]						
Male (n=55)	75.7 (66.3, 83.6)	95.0 (86.1, 99.0)				
Female (n=44)	77.6 (68.0, 85.4)	100 (88.4, 100)				
P value	0.8678	0.5480				

[a]Summary result calculated across all readers for Studies A, B, and C at baseline.

[b]Summary result calculated across all readers for Study B.

[c]Summary result calculated across all readers for Study C.

Sensitivity (PPA)/specificity (NPA) for parkinsonian syndrome (PS) was calculated based on PS present *vs.* PS absent; Sensitivity (PPA)/specificity (NPA) for dementia with Lewy bodies (DLB) was calculated based on Probably DLB *vs.* Non-DLB; Sensitivity (PPA)/specificity (NPA) for whole population was calculated based on SDD present *vs.* SDD absent.

P value is from Fisher's exact test.

CI, confidence interval; n, number of subjects included in the analysis; NPA, negative percent agreement; PPA, positive percent agreement; SDDD, striatal dopaminergic deficit disorder

Table 6 Sensitivity (PPA) and specificity (NPA) from on-site image reads between male and female subjects Intent to diagnose population

Reference Clinical Diagnosis						
	Parkinsonian Syndrome (PS; SDDD)		Dementia with Lewy Bodies (DLB; SDDD)		Whole Population	
	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)
Mean Results[a]						
Male (n=352)	91.3 (86.8, 94.6)	93.0 (86.6, 96.9)	90.9 (80.0, 97.0)	82.5 (70.9, 90.9)	91.2 (87.3, 94.2)	89.3 (83.7, 93.4)
Female (n=262)	87.6 (82.0, 92.0)	85.5 (75.0, 92.8)	88.2 (72.5, 96.7)	80.6 (68.6, 89.6)	87.7 (82.6, 91.8)	83.2 (75.7, 89.2)
P value	0.2583	0.1255	0.7271	0.8209	0.2379	0.1300

Citation: Grosset DG, O'Brien JT, Oertel WH, et al. Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia. *J Neurol Stroke*. 2014;1(2):42–58. DOI: 10.15406/jnsk.2014.01.00008

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al.   **50**

Table Continued....

Reference Clinical Diagnosis						
	Parkinsonian Syndrome (PS; SDDD)		Dementia with Lewy Bodies (DLB; SDDD)		Whole Population	
	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)
Month 12[b]						
Male (n=118)			90.9 (80.0, 97.0)	82.5 (70.9, 90.9)		
Female (n=96)			88.2 (72.5, 96.7)	80.6 (68.6, 89.6)		
P value			0.7271	0.8209		
Month 18[c]						
Male (n=56)	82.9 (66.4, 93.4)	95.2 (76.2, 99.9)				
Female (n=45)	80.0 (63.1, 91.6)	80.0 (44.4, 97.5)				
P value	1.0000	0.2369				
Month 36[c]						
Male (n=53)	82.4 (65.5, 93.2)	89.5 (66.9, 98.7)				
Female (n=44)	85.3 (68.9, 95.0)	80.0 (44.4, 97.5)				
P value	1.0000	0.5920				

[a]Summary results calculated across all studies and time points. For Study B, month 12 reference clinical diagnosis was used.

[b]Summary result calculated for Study B.

[c]Summary result calculated for Study C.

Sensitivity (PPA)/specificity (NPA) for parkinsonian syndrome (PS) was calculated based on PS present *vs*. PS absent; Sensitivity (PPA)/specificity (NPA) for dementia with Lewy bodies (DLB) was calculated based on Probably DLB *vs*. Non-DLB; Sensitivity (PPA)/specificity (NPA) for whole population was calculated based on SDD present *vs*. SDD absent.

P value is from Fisher's exact test.

CI, confidence interval; n, number of subjects included in the analysis; NPA, negative percent agreement; PPA, positive percent agreement; SDDD, striatal dopaminergic deficit disorder

Effect of age on diagnostic performance

Figure 2 displays sensitivity (PPA) and specificity (NPA) in subjects < and ≥ 65years (yrs) and 75yrs, broken out by disease state (PS and DLB), in which BIE reads at baseline were used. In subjects with PS, sensitivity and specificity was lower in older subjects than younger subjects, however the difference was only statistically significant for specificity when using 65yrs as the cutoff. In subjects with DLB, sensitivity was higher in older subjects when using 65 yrs as the cutoff, but lower if 75yrs was used. Sensitivity remained statistically significantly higher in older subjects using the 65-yr cutoff at the Month 12 assessment. Specificity was roughly equivalent, regardless of which age cutoff was used. In the whole population, sensitivity was statistically significantly higher in younger subjects using either cutoff; specificity was only higher in younger subjects when 65 yrs was used as the cutoff (Tables 7&8). When the on-site image reads were used, the only statistically significant differences noted were that specificity was higher at baseline in younger subjects using the 65-yr cutoff and the whole population (Tables 9 and 10).

Table 7 Sensitivity (PPA) and specificity (NPA) from blinded image evaluation between <65 and ≥65 yrs subjects Values are mean results across all readers. Intent to diagnose population

Reference Clinical Diagnosis						
	Parkinsonian Syndrome (PS; SDDD)		Dementia with Lewy Bodies (DLB; SDDD)		Whole Population	
	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)
Baseline[a]						
<65 yrs (n=204)	92.3 (89.7, 94.4)	94.8 (91.1, 97.3)	57.1 (34.0, 78.2)	90.7 (79.7, 96.9)	91.0 (88.3, 93.2)	94.0 (90.6, 96.5)
≥65 yrs (n=349)	89.7 (86.5, 92.3)	89.0 (83.4, 93.3)	80.6 (74.6, 85.6)	90.0 (86.4, 92.9)	86.8 (84.0, 89.2)	89.7 (86.8, 92.1)
P value	0.1808	0.0378	0.0226	1.0000	0.0240	0.0384

Citation: Grosset DG, O'Brien JT, Oertel WH, et al. Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia. *J Neurol Stroke.* 2014;1(2):42–58. DOI: 10.15406/jnsk.2014.01.00008

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al.   **51**

Reference Clinical Diagnosis

	Parkinsonian Syndrome (PS; SDDD)		Dementia with Lewy Bodies (DLB; SDDD)		Whole Population	
	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)
Month 12[b]						
<65 yrs (n=23)			47.6 (25.7, 70.2)	89.6 (77.3, 96.5)		
≥65 yrs (n=186)			81.5 (75.6, 86.4)	93.2 (89.9, 95.8)		
P value			0.0011	0.3682		
Month 18[c]						
<65 yrs (n=60)	83.3 (75.4, 89.5)	94.9 (85.9, 98.9)				
≥65 yrs (n=42)	73.1 (62.9, 81.8)	97.0 (84.2, 99.9)				
P value	0.0903	1.0000				
Month 36[c]						
<65 yrs (n=58)	80.7 (72.3, 87.5)	94.7 (85.4, 98.9)				
≥65 yrs (n=41)	71.3, (60.6, 80.5)	100 (89.4, 100)				
P value	0.1320	0.2955				

[a]Summary result calculated across all readers for Studies A, B, and C at baseline.

[b]Summary result calculated across all readers for Study B.

[c]Summary result calculated across all readers for Study C.

Sensitivity (PPA)/specificity (NPA) for parkinsonian syndrome (PS) was calculated based on PS present *vs.* PS absent; Sensitivity (PPA)/specificity (NPA) for dementia with Lewy bodies (DLB) was calculated based on Probably DLB *vs.* Non-DLB; Sensitivity (PPA)/specificity (NPA) for whole population was calculated based on SDD present *vs.* SDD absent.

P value is from Fisher's exact test.

CI, confidence interval; n, number of subjects included in the analysis; NPA, negative percent agreement; PPA, positive percent agreement; SDDD, striatal dopaminergic deficit disorder.

Figure 2 Sensitivity (PPA) and specificity (NPA) in young *vs.* old subjects with PS and DLB. Sensitivity (PPA) and specificity (NPA), blinded image evaluation reads at baseline in subjects with PS (parkinsonian syndrome) and DLB (dementia with Lewy bodies). *P <0.05; **P <0.01.

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al.   52

Table 8 Sensitivity (PPA) and specificity (NPA) from blinded image evaluation between <75 and ≥75yrs subjects. Values are mean results across all readers. Intent to diagnose population

Reference Clinical Diagnosis						
	Parkinsonian Syndrome (PS; SDDD)		Dementia with Lewy Bodies (DLB; SDDD)		Whole Population	
	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)
Baseline[a]						
<65 yrs (n=204)	92.3 (89.7, 94.4)	94.8 (91.1, 97.3)	57.1 (34.0, 78.2)	90.7 (79.7, 96.9)	91.0 (88.3, 93.2)	94.0 (90.6, 96.5)
≥65 yrs (n=349)	89.7 (86.5, 92.3)	89.0 (83.4, 93.3)	80.6 (74.6, 85.6)	90.0 (86.4, 92.9)	86.8 (84.0, 89.2)	89.7 (86.8, 92.1)
P value	0.1808	0.0378	0.0226	1.0000	0.0240	0.0384
Month 12[b]						
<65 yrs (n=23)			47.6 (25.7, 70.2)	89.6 (77.3, 96.5)		
≥65 yrs (n=186)			81.5 (75.6, 86.4)	93.2 (89.9, 95.8)		
P value			0.0011	0.3682		
Month 18[c]						
<65 yrs (n=60)	83.3 (75.4, 89.5)	94.9 (85.9, 98.9)				
≥65 yrs (n=42)	73.1 (62.9, 81.8)	97.0 (84.2, 99.9)				
P value	0.0903	1.0000				
Month 36[c]						
<65 yrs (n=58)	80.7 (72.3, 87.5)	94.7 (85.4, 98.9)				
≥65 yrs (n=41)	71.3, (60.6, 80.5)	100 (89.4, 100)				
P value	0.1320	0.2955				

aSummary result calculated across all readers for Studies A, B, and C at baseline.

bSummary result calculated across all readers for Study B.

cSummary result calculated across all readers for Study C.

Sensitivity (PPA)/specificity (NPA) for parkinsonian syndrome (PS) was calculated based on PS present *vs*. PS absent; Sensitivity (PPA)/specificity (NPA) for dementia with Lewy bodies (DLB) was calculated based on Probably DLB *vs*. Non-DLB; Sensitivity (PPA)/specificity (NPA) for whole population was calculated based on SDD present *vs*. SDD absent.

P value is from Fisher's exact test.

CI, confidence interval; n, number of subjects included in the analysis; NPA, negative percent agreement; PPA, positive percent agreement; SDDD, striatal dopaminergic deficit disorder.

Table 9 Sensitivity (PPA) and specificity (NPA) from on-site image reads between <65 and ≥65 yrs subjects. Intent to diagnose population

Reference Clinical Diagnosis						
	Parkinsonian Syndrome (PS; SDDD)		Dementia with Lewy Bodies (DLB; SDDD)		Whole Population	
	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)
Mean Results[a]						
<65 yrs (n=235)	89.7 (85.0, 93.4)	94.2 (87.8, 97.8)	77.8 (40.0, 97.2)	81.3 (54.4, 96.0)	89.3 (84.6, 92.9)	92.4 (86.1, 96.5)
≥65 yrs (n=379)	89.5 (84.3, 93.5)	85.0 (75.3, 92.0)	91.3 (82.8, 96.4)	81.7 (73.1, 88.4)	90.0 (85.8, 93.3)	83.1 (76.9, 88.1)
P value	1.0000	0.0468	0.2247	1.0000	0.8834	0.0242

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al.　53

Table Continued....

Reference Clinical Diagnosis						
	Parkinsonian Syndrome (PS; SDDD)		Dementia with Lewy Bodies (DLB; SDDD)		Whole Population	
	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)
Month 12[b]						
<65 yrs (n=25)			77.8 (40.0, 97.2)	81.3 (54.4, 96.0)		
≥65 yrs (n=189)			91.3 (82.8, 96.4)	81.7 (73.1, 88.4)		
P value			0.2247	1.0000		
Month 18[c]						
<65 yrs (n=59)	82.1 (66.5, 92.5)	95.0 (75.1, 99.9)				
≥65 yrs (n=42)	80.6 (62.5, 92.5)	81.8 (48.2, 97.7)				
P value	1.0000	0.2814				
Month 36[c]						
<65 yrs (n=58)	82.1 (66.5, 92.5)	89.5 (66.9, 98.7)				
≥65 yrs (n=39)	86.2 (68.3, 96.1)	80.0 (44.4, 97.5)				
P value	0.7473	0.5920				

[a]Summary results calculated across all studies and time points. For Study B, month 12 reference clinical diagnosis was used.

[b]Summary result calculated for Study B.

[c]Summary result calculated for Study C.

Sensitivity (PPA)/specificity (NPA) for parkinsonian syndrome (PS) was calculated based on PS present *vs.* PS absent; Sensitivity (PPA)/specificity (NPA) for dementia with Lewy bodies (DLB) was calculated based on Probably DLB *vs.* Non-DLB; Sensitivity (PPA)/specificity (NPA) for whole population was calculated based on SDD present *vs.* SDD absent. P value is from Fisher's exact test.

CI, confidence interval; n, number of subjects included in the analysis; NPA, negative percent agreement; PPA, positive percent agreement; SDDD, striatal dopaminergic deficit disorder.

Table 10 Sensitivity (PPA) and specificity (NPA) from on-site image reads between <75 and ≥75 yrs subjects. Intent to diagnose population

	Reference Clinical Diagnosis					
	Parkinsonian Syndrome (PS; SDDD)		**Dementia with Lewy Bodies (DLB; SDDD)**		**Whole Population**	
	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)
Mean Results[a]					89.3 (86.0, 92.1)	86.4 (81.1, 90.6)
<75 yrs (n=460)	89.2 (85.6, 92.2)	89.1 (83.3, 93.4)	89.8 (77.8, 96.6)	78.2 (65.0, 88.2)		
≥75 yrs (n=154)	93.0 (80.9, 98.5)	100 (81.5, 100)	90.0 (76.3, 97.2)	84.3 (73.6, 91.9)	91.6 (83.4, 96.5)	87.5 (78.7, 93.6)
P value	0.6004	0.2237	1.0000	0.4864	0.6932	0.8547
Month 12b						
<75 yrs (n=104)			89.8 (77.8, 96.6)	78.2 (65.0, 88.2)		
≥75 yrs (n=110)			90.0 (76.3, 97.2)	84.3 (73.6, 91.9)		
P value			1.0000	0.4864		

Citation: Grosset DG, O'Brien JT, Oertel WH, et al. Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia. *J Neurol Stroke.* 2014;1(2):42–58. DOI: 10.15406/jnsk.2014.01.00008

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al. **54**

Table Continued....

	Reference Clinical Diagnosis					
	Parkinsonian Syndrome (PS; SDDD)		Dementia with Lewy Bodies (DLB; SDDD)		Whole Population	
	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)	Sensitivity % (95% CI)	Specificity % (95% CI)
Month 18c						
<75 yrs (n=92)	81.0 (69.1, 89.8)	89.7 (72.6, 97.8)				
≥75 yrs (n=9)	85.7 (42.1, 99.6)	100 (15.8, 100)				
P value	1.0000	1.0000				
Month 36c						
<75 yrs (n=89)	83.9 (72.3, 92.0)	85.2 (66.3, 95.8)				
≥75 yrs (n=8)	83.3 (35.9, 99.6)	100 (15.8, 100)				
P value	1.0000	1.0000				

[a]Summary results calculated across all studies and time points. For Study B, month 12 reference clinical diagnosis was used.

[b]Summary result calculated for Study B.

[c]Summary result calculated for Study C.

Sensitivity (PPA)/Specificity (NPA) for Parkinsonian Syndrome (PS) was calculated based on PS present *vs.* PS absent; Sensitivity (PPA)/Specificity (NPA) for Dementia with Lewy Bodies (DLB) was calculated based on Probably DLB *vs.* Non-DLB; Sensitivity (PPA)/specificity (NPA) for whole population was calculated based on SDD present *vs.* SDD absent. P value is from Fisher's exact test.

CI, confidence interval; n, number of subjects included in the analysis; NPA, negative percent agreement; PPA, positive percent agreement; SDDD, striatal dopaminergic deficit disorder.

Effect of disease state on diagnostic performance

Figure 3 displays sensitivity (PPA) and specificity (NPA) in subjects with PS *vs.* DLB, broken out by gender and age using both 65-yr and 75-yr cutoffs, using BIE results at baseline. Overall, sensitivity and specificity were numerically lower (not tested for P-value) in subjects with DLB compared with subjects with PS.

Figure 3 Sensitivity (PPA) and specificity (NPA) in subjects with PS *vs.* DLB. Sensitivity (PPA) and specificity (NPA), read at baseline in subjects with PS (parkinsonian syndrome) and DLB (dementia with Lewy bodies).

Effects of additional covariates on diagnostic performance

To identify the significant predictors for effects on sensitivity (PPA) and specificity (NPA), a multiple logistic regression model was used. The following covariates were included in the model: disease state (DLB *vs.* PS), age (as a continuous variable), gender (male *vs.* female), type of reader (blinded *vs.* on-site), and duration of follow-up (as a continuous variable). Table 11 summarizes the results for the

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al.

55

ITD population. The numbers of observations is the total number of readings from all readers (blinded and on-site) across all time points in all studies (Table 12). For sensitivity, all covariates were significant independent predictors (P<0.05). For specificity, only disease state and type of reader were significant predictors. Results were similar for the PP population and for individual logistical regression for both populations (Tables 12 and 13).

Table 11 Logistic regression for ioflupane (^{123}I) sensitivity (PPA) and specificity (NPA) with covariate(s)-ITD population

	Statistics	Logistic Regression with All Covariates		Individual Logistic Regression	
		P-value	Odds ratio (95% CI)	P-value	Odds ratio (95% CI)
Sensitivity (PPA)					
Number of Observations	2485				
Number of Observations with True Positive	2139 (86.1%)				
Disease state (DLB *vs.* PS)		0.0028	0.642 (0.480, 0.859)	0.0001	0.612 (0.481, 0.780)
Age (yrs)[a]		0.0086	0.982 (0.968, 0.995)	0.0001	0.977 (0.966, 0.989)
Gender (Male *vs.* Female)		0.0031	1.421 (1.126, 1.794)	0.0030	1.412 (1.124, 1.773)
Reading (Blinded *vs.* On-site)[b]		0.0016	0.622 (0.463, 0.835)	0.0063	0.667 (0.499, 0.892)
Duration of follow-up (months)[a]		<0.0001	0.970 (0.961, 0.979)	<0.0001	0.974 (0.966, 0.982)
Specificity (NPA)					
Number of Observations	1811				
Number of Observations with True Negative	1632 (90.1%)				
Disease state (DLB *vs.* PS)		0.0048	0.547 (0.360, 0.832)	0.0017	0.588 (0.423, 0.819)
Age (yrs)[a]		0.4975	1.006 (0.988, 1.024)	0.1189	0.989 (0.975, 1.003)
Gender (Male *vs.* Female)		0.0839	0.754 (0.548, 1.038)	0.1981	0.814 (0.595, 1.114)
Reading (Blinded *vs.* On-site)[b]		<0.0001	2.307 (1.674, 3.180)	<0.0001	2.322 (1.688, 3.194)
Duration of follow-up (months)[a]		0.0710	1.017 (0.999, 1.037)	0.0491	1.018 (1.000, 1.036)

[a]Age and duration of follow-up are treated as continuous in the logistic regression model.

[b]PDT408 only has institutional (on-site) reads.

CI, confidence interval; DLB, dementia with lewy bodies; ITD, intent to diagnose; n, number of subjects included in the analysis; NPA, negative percent agreement; PPA, positive percent agreement; PS, parkinsonian syndrome; yrs, years

Table 12 Number of readings, by reader type and study, for sensitivity (PPA) and specificity (NPA)

Study ID	Reader	Sensitivity	Specificity
Study A	Blinded	790	310
Study B	Blinded	474	772
Study C	Blinded	623	275
Study A	On-site	158	62
Study B	On-site	183	271
Study C	On-site	209	91
Study D	On-site	48	30
Total		2485	1811
1. ITD Population			
Study ID	**Reader**	**Sensitivity**	**Specificity**
Study A	Blinded	575	210
Study B	Blinded	472	767
Study C	Blinded	605	275

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al.　**56**

Table Continued....

Study ID	Reader	Sensitivity	Specificity
Study A	On-site	115	42
Study B	On-site	173	267
Study C	On-site	203	91
Study D	On-site	47	30
Total		2190	1682
PP Population			

Table 13 Logistic regression for ioflupane (^{123}I) sensitivity (PPA) and specificity (NPA) with covariate(s)-PP population

		Logistic Regression with All Covariates		Individual Logistic Regression	
	Statistics	P-value	Odds ratio (95% CI)	P-value	Odds ratio (95% CI)
Sensitivity (PPA)					
Number of Observations	2190				
Number of Observations with True Positive	1855 (84.7 %)				
Disease state (DLB *vs.* PS)		0.0090	0.674 (0.501, 0.906)	0.0025	0.685 (0.537, 0.875)
Age (yrs)[a]		0.0646	0.987 (0.973, 1.001)	0.0055	0.983 (0.972, 0.995)
Gender (Male *vs.* Female)		0.0017	1.463 (1.154, 1.856)	0.0013	1.467 (1.161, 1.853)
Reading (Blinded *vs.* On-site)[b]		0.0035	0.643 (0.478, 0.865)	0.0081	0.673 (0.502, 0.902)
Duration of follow-up (months)[a]		< 0.0001	0.973 (0.964, 0.983)	< 0.0001	0.977 (0.969, 0.986)
Specificity (NPA)					
Number of Observations	1682				
Number of Observations with True Negative	1518 (90.2 %)				
Disease state (DLB *vs.* PS)		0.0003	0.421 (0.264, 0.671)	0.0008	0.536 (0.373, 0.771)
Age (yrs)[a]		0.0722	1.017 (0.998, 1.036)	0.3755	0.993 (0.979, 1.008)
Gender (Male *vs.* Female)		0.0629	0.727 (0.520, 1.017)	0.1782	0.799 (0.576, 1.108)
Reading (Blinded *vs.* On-site)[b]		< 0.0001	2.628 (1.884, 3.665)	<0.0001	2.609 (1.876, 3.629)
Duration of follow-up (months)[a]		0.1181	1.016 (0.996, 1.036)	0.0546	1.018 (1.000, 1.036)

aAge and duration of follow-up are treated as continuous in the logistic regression model.

bPDT408 only has institutional (on-site) reads.

CI, confidence interval; DLB, dementia with lewy bodies; n, number of subjects included in the analysis; NPA, negative percent agreement; PP, per protocol; PPA, positive percent agreement; PS, parkinsonian syndrome; yrs, years

Discussion

This subgroup analysis is the first to evaluate the effects of gender and age on the diagnostic performance of ioflupane (^{123}I) imaging to detect the presence or absence of an SDD in subjects with a movement disorder or dementia. Pooling the 4 clinical trials provided a large dataset (ITD N =726) to enable this analysis. Although PS and DLB are different disorders, they share the common underlying pathology of striatal dopaminergic deficit. Additionally, there is some overlap in symptomatology, with cognitive impairment observed in patients with PS and DLB patients presenting with motor symptoms. These symptoms accumulate and become more profound with progression of the disease. For this reason, we analyzed the disorders individually as well as the whole population. The BIE image reads which were performed in 3 of the 4 studies, tended to yield more statistically significant differences between subgroups.

Overall, sensitivity and specificity were high in all subgroups analyzed. However, gender had some effect on diagnostic performance in PS and the whole population at baseline when BIE reads were used. Sensitivity was lower and specificity was higher in females compared with males. Studies evaluating gender in PD have shown that differences exist, such as increased prevalence in males (60%), delayed age at onset in females, as well as females more frequently presenting with tremor; for patients presenting with tremor, a slower rate of deterioration was observed 16. Females also had 16% higher ioflupane (^{123}I) binding than males at both the onset of disease and throughout 10 years of follow-up 16. Differences in motor phenotypes have been observed, with males exhibiting symmetrical upper-body disease, whereas females exhibited more postural instability 17. Non-motor phenotypic differences have also been noted, with males having more cognitive impairment, rapid eye movement sleep behavior disorder, orthostatic hypotension, and sexual dysfunction 17.

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al. 57

These findings suggest an overall milder course of disease in females, which might explain some of our observations in terms of potential relationships to accuracy of clinical diagnosis, the reference standard used in this study. Higher ioflupane (^{123}I) binding in females may make it more difficult, or at a minimum, delay image interpretation as being abnormal, reducing the sensitivity of detecting an SDDD in the early stages of the disease. This is borne out by the fact that sensitivity in females approximated that in males later in the disease process (month 18 and month 36, Figure 1). On the other hand, because a diagnosis of PD in males is more common (2/3 of all cases) and relatively straightforward, it may be easier to exclude a diagnosis of PD in females (less common; 1/3 of all cases), which would increase specificity. The observed fluctuation in diagnostic performance over time (comparing baseline data with 18 and 36 months) is more likely associated with less precision in the reference standard than in inaccuracies of the interpretation of the SPECT images. This is particularly true, because the 18- and 36-month clinical diagnoses were established based on independent review by movement disorder specialists of videotapes, not by a clinical consensus panel (Study C) [12]. Furthermore, the inter-reader agreement, as measured by kappa, was very good/almost perfect [9,12,18,19], which further supports our contention that the observed fluctuations in diagnostic performance were not due to inaccuracies in the interpretations of the SPECT images.

Differences associated with gender in PS were not observed in subjects with DLB, despite recent observations that the incidence of DLB is higher in males [20]. This can likely by explained by the smaller sample size of DLB subjects as compared to PS in our analysis, which was also substantiated by Savica et al. [20] by their finding that the overall incidence rate of DLB is lower than that of PD [20].

In spite of all subgroup results being high, age had a slight effect on diagnostic performance, with sensitivity and specificity tending to be lower in older than younger subjects with PS. However, statistically significant differences were only observed for specificity when 65 yrs was used as the cutoff. Sensitivity was also lower in the whole population, reaching statistical significance using both age cutoffs, whereas specificity was only statistically significantly lower in older subjects when the 65-yr cutoff was used. This may be explained by increasing presence of multiple comorbid conditions with advanced age that could complicate clinical diagnosis. Additionally, older individuals may have mixed pathologies that make clinical diagnosis more challenging. Lastly, the decreased binding of ioflupane (^{123}I) with normal aging [3-6] could make it more difficult to discriminate normal from abnormal images later in life.

Clinical diagnosis had an effect on the diagnostic performance of ioflupane (^{123}I) imaging. Overall, even though the mean values for sensitivity and specificity in the whole population were high, it tended to be slightly lower in subjects with DLB compared with subjects with PS (statistical difference was not tested). This can most likely be explained by the fact that dementia subtype is more difficult to diagnose than PS, and the reduced accuracy can be attributed to less precision in the reference standard (i.e., the clinical diagnosis of DLB [21] or other dementia subtypes (with or without SDD), rather than inaccuracies in the interpretations of the SPECT images.

When a multiple logistic regression model was used, all covariates (disease state DLB *vs.* PS), age, gender (male *vs.* female), type of reader (blinded *vs.* on-site) and duration of follow-up) were significant predictors of the model effect on sensitivity. For specificity, only disease state and type of reader were significant predictors. The observation that age and gender did not affect specificity in the

multiple logistic regression model is important and supports the robust performance and high accuracy of this diagnostic test. Age and gender had a statistically significant effect on sensitivity, which may be explained by the points raised earlier. Additional research may be needed to further delineate whether the effects observed are reproducible and clinically relevant.

This subgroup analysis had some limitations. This was an exploratory analysis, and as such, unadjusted p-values were calculated. If corrections for multiple comparisons had been made, the results may have been different. Image assessments were only performed visually. If quantification procedures had been included, differences may have been observed in the sensitivity and specificity results. Although clinical diagnosis is considered a valuable reference standard in developing radiopharmaceuticals for movement disorders and dementia [22], the definitive truth standard is neuropathological confirmation of brain tissue at autopsy. However, it is impractical to design clinical trials to span the life-expectancy of the study subjects, and so clinical diagnosis is the best alternative. For this reason, in our paper, in addition to sensitivity and specificity, we also used the terms PPA and NPA (mathematically identical calculations, but emphasizing our limitations of not being the truth standard). Despite taking measures to minimize errors in clinical diagnosis, such as using panels of experts, inaccuracies likely occurred, and may be were responsible for the reductions observed in sensitivity and specificity. Additionally, age and gender had some statistically significant effects on the diagnostic performance of ioflupane (^{123}I) imaging, although to what extent these differences are clinically relevant is unknown. The observed effects should be taken into consideration and allowed for when assessing patients presenting with varying diagnostic states.

Conclusion

This subgroup analysis showed that gender and age have some effect on the diagnostic performance of ioflupane (^{123}I) imaging in subjects with movement disorders or dementia when clinical diagnosis is used as the reference standard. Overall, sensitivity and specificity were high. Statistically significant differences were observed in some comparisons. Sensitivity was slightly reduced, though still diagnostically useful, above the age of 75. In subjects with PS, sensitivity was higher in males, whereas specificity was higher in females. Multiple logistic regression model analysis demonstrated that all tested covariates (including age and gender) were significant predictors for sensitivity, but not for specificity, where only disease state and type of reader were significant predictors. To what extent these differences are clinically relevant remains to be elucidated. Additional research may provide further clarification on these issues.

Acknowledgement

Age, gender, and diagnostic performance of ioflupane I123 injection (DaTscan™) brain imaging in patients with movement disorders and/or dementia

Copyright:
©2014 Grosset et al. **58**

IG McKeith: Received grants and personal fees for speakers' bureaus and consultancy from GE Healthcare.

Z Walker: Received grants and personal fees for research, consulting, speakers' bureaus, lectures, and travel expenses from GE Healthcare; personal fees for consultancy from Bayer Healthcare and Novartis; and grants from Lundbeck.

K Tatsch: Received personal fees for performing DaTscan SPECT image reads during clinical trials and honoraria for lectures from GE Healthcare.

E Tolosa: Received personal fees for research, lectures and consultancy from Novarits, TEVA, Boehringer Ingelheim, UCB, Solvay, and Lundbeck; grants from the Spaniard Network, Michael J. Fox Foundation, and Fondo de Investigaciones Sanitarias de la Seguridad Social.

PF Sherwin: Full-time employee of GE Healthcare.

ID Grachev: Full-time employee of GE Healthcare at the time of the study and does not hold any stocks or shares, or have other financial competing interests.

Conflicts of interest

References

1. Grachev ID, Apkarian AV. Chemical network of the living human brain. Evidence of reorganization with aging. *Brain Res Cogn Brain Res*. 2001;11(2):185–197.

2. Grachev ID, Swarnkar A, Szeverenyi NM,et al. Aging alters the multichemical networking profile of the human brain: an in vivo (1) H–MRS study of young versus middle–aged subjects. *J Neurochem*. 2001;77(1):292–303.

3. van Dyck CH, Seibyl JP, Malison RT, et al. Age–related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. *Am J Geriatr Psychiatry*. 2002;10(1):36–43.

4. Eusebio A, Azulay JP, Ceccaldi M, et al. Voxel–based analysis of whole–brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects. *Eur J Nucl Med Mol Imaging*. 2012;39(11):1778–1783.

5. Lavalaye J, Booij J, Reneman L, et al. Effect of age and gender on dopamine transporter imaging with [123I]FP–CIT SPET in healthy volunteers. *Eur J Nucl Med*. 2000;27(7):867–869.

6. Varrone A, Dickson JC, Tossici–Bolt L, et al. European multicentre database of healthy controls for [123I]FP–CIT SPECT (ENC–DAT): age–related effects, gender differences and evaluation of different methods of analysis. *Eur J Nucl Med Mol Imaging*. 2013;40(2):213–227.

7. Schapira AH, Albrecht S, Barone P, et al. Rationale for delayed–start study of pramipexole in Parkinson's disease: the PROUD study. *Mov Disord*. 2010;25(11):1627–1632.

8. Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed–start trial. *Lancet Neurol*. 2013;12(8):747–755. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I–FP–CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. *Lancet Neurol*. 2007;6(4):305–313.

9. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]–FP–CIT SPECT imaging: the [123I]–FP–CIT study group. *Mov Disord*. 2000;15(3):503–510.

10. O'Brien JT, McKeith IG, Walker Z, et al. Diagnostic accuracy of 123I–FP–CIT SPECT in possible dementia with Lewy bodies. *Br J Psychiatry*. 2009;194(1):34–39.

11. Marshall VL, Reininger CB, Marquardt M, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3–year European multicenter study with repeat [123I]FP–CIT SPECT. *Mov Disord*. 2009;24(4):500–508.

12. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP–CIT single photon emission computed tomography imaging and autopsy. *J Neurol Neurosurg Psychiatry*. 2007;78(11):1176–1181.

13. Catafau AM, Tolosa E, DaTSCAN. Clinically Uncertain Parkinsonian Syndromes Study GroupImpact of dopamine transporter SPECT using 123I–Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. *Mov Disord*. 2004;19(10):1175–1182.

14. Tolosa E, Borght TV, Moreno E, DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group (2007) Accuracy of DaTSCAN (123I–Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2–year follow–up of an open–label study. Mov Disord 22(16):2346–2351.

15. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, et al. (2007) Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 78(8):819–824.

16. Szewczyk–Krolikowski K, Tomlinson P, Nithi K, Wade–Martins R, Talbot K, et al. (2014) The influence of age and gender on motor and non–motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord 20(1):99–105.

17. Altman DG (1991) Practical statistics for medical research.(1st edn), London, Chapman and Hall.

18. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174.

19. Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, et al. (2013) Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol 70(11):1396–1402.

20. McKeith IG (2006) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 9(3 Suppl):417–423.

21. Gorovets A, Marzella L, Rieves D, Yang L (2013) Efficacy considerations for U.S. Food and Drug Administration approval of diagnostic radiopharmaceuticals. J Nucl Med 54(8):1479–1484.